{
    "organizations": [],
    "uuid": "df2dceecf9cbbb3a96a42697ea9681a5c9a88a41",
    "author": "",
    "url": "https://www.reuters.com/article/brief-mimedxs-amniofix-injectable-grante/brief-mimedxs-amniofix-injectable-granted-rmat-designation-by-fda-idUSFWN1QR0UP",
    "ord_in_thread": 0,
    "title": "BRIEF-Mimedx's Amniofix Injectable Granted RMAT Designation By FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 9 (Reuters) - Mimedx Group Inc:\n* AMNIOFIX INJECTABLE GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION BY THE FDA FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE\n* SAYS ‍FDA CONFIRMED DETERMINATION THAT MIMEDX ALLOGENEIC MICRONIZED DHACM FOR TREATMENT OF OA OF KNEE MEETS CRITERIA FOR RMAT DESIGNATION​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-09T19:49:00.000+02:00",
    "crawled": "2018-03-09T20:06:06.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "mimedx",
        "group",
        "inc",
        "amniofix",
        "injectable",
        "granted",
        "regenerative",
        "medicine",
        "advanced",
        "therapy",
        "rmat",
        "designation",
        "fda",
        "treatment",
        "osteoarthritis",
        "knee",
        "say",
        "confirmed",
        "determination",
        "mimedx",
        "allogeneic",
        "micronized",
        "dhacm",
        "treatment",
        "oa",
        "knee",
        "meet",
        "criterion",
        "rmat",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}